1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
(
- Contribution to journal › Article
- 2011
-
Mark
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
(
- Contribution to journal › Article
- 2010
-
Mark
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
(
- Contribution to journal › Article
-
Mark
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
(
- Contribution to journal › Article
- 2009
-
Mark
Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph plus ) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy
(
- Contribution to journal › Published meeting abstract
-
Mark
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
(
- Contribution to journal › Article
- 2008
-
Mark
Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy
(
- Contribution to journal › Published meeting abstract